Summary
Escherichia coli with high-level fluoroquinolone resistance were isolated from feces and/or various body sites of 16 cancer patients who were on oral fluoroquinolone prophylaxis. Population analysis of fecal isolates in 11 patients showed that fluoroquinoloneresistantE. coli was the only aerobic gram-negative bacillus present and exhibited a relatively homogenous fluoroquinolone MIC distribution. Molecular typing by pulsed field gel electrophoresis of chromosomal DNA digests or by random amplified polymorphic DNA fingerprinting confirmed the clonal nature of gastrointestinal tract colonization withE. coli. Genotyping of ten colonies picked from the same fecal culture demonstrated identical strains in four of four patients examined. Identical genotypes from the same patient were isolated over prolonged periods of time in 12 of 12 cases examined, with one patient (with the longest follow-up of 14 months) who lost his initial genotype and became persistently colonized with a new genotype. In the 11 patients who developed infection due to fluoroquinolone-resistantE. coli, molecular typing also indicated that fecal colonization was associated with, and presumably preceded infection due to an indistinguishable genotype of fluoroquinolone-resistantE. coli.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Cruciani, M., Cruciani, M., Rampazzo, R., Malena, M., Lazzarini, L., Todeschini, G., Messori, A., Concia, E.: Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin. Infect. Dis. 23 (1996) 795–805.
Engels, E., Lau, J., Barza, M.: Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J. Clin. Oncol. 16 (1998) 1179–1187.
Carratalá, J., Fernandez-Sevilla, A., Tubau, F., Dominguez, M. A., Gudiol, F.: Emergence of fluoroquinolone-resistantEscherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob. Agents Chemother. 40 (1996) 503–505.
Cometta, A., Calandra, T., Bille, J., Glauser, M. P.:Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia (letter). N. Engl. J. Med. 330 (1994) 1240–1241.
Kern, W. V., Andriof, E., Oethinger, M., Kern, P., Hacker, J., Marre, R.: Emergence of fluoroquinolone-resistantEscherichia coli at a cancer center. Antimicrob. Agents Chemother. 38 (1994) 681–687.
Oethinger, M., Conrad, S., Kaifel, K., Cometta, A., Bille, J., Klotz, G. Glauser, M. P., Marre, R., Kern, W. V.: Molecular epidemiology of fluoroquinolone-resistantEscherichia coli bloodstream isolates from patients admitted to European cancer centers. Antimicrob. Agents Chemother. 40 (1996) 387–392.
Arbeit, R. D., Arthur, M., Dunn, R., Kim C., Selander, R. K., Goldstein, R.: Resolution of recent evolutionary divergence amongEscherichia coli from related lineages: the application of pulsed field electrophoresis to molecular epidemiology. J. Infect. Dis. 161 (1990) 230–235.
Gray, L. D.:Escherichia, Salmonella, Shigella, andYersinia. In:Murray, P., Baron, E. J., Pfaller, M. A., Tenover, F. C., Yolken, R. H. (eds.): Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington DC 1995, pp. 450–458.
National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd ed., approved standard M7-A2. Villanova, PA, NCCLS, 1990.
Berg, D. E., Akopyants, N. S., Kersulyte, D.: Fingerprinting microbial genomes using the RAPD or AP-PCR method. Methods. Mol. Cell Biol. 5 (1994) 13–24.
Wang, G., Whittam, T. S., Berg, C. M., Berg, D. E.: RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing related bacterial strains. Nucleic Acids Res. 21 (1993) 5930–5933.
Wendt, C. Hollis, R., Pfaller, M., Wenzel, R., Herwaldt, L.: Molecular epidemiology of bacteremia due toEscherichia coli. Abstracts 7th European Congress of Clinical Microbiology and Infectious Diseases, 1995, abstr. 1106.
Lindin-Janson, G., Kaijser, B., Lincoln, K., Olling, S., Wedel, H.: The homogeneity of the fecal coliform flora of normal schoolgirld, characterized by serological and biochemical properties. Med. Microbiol. Immunol. 164 (1978) 247–253.
Brumfitt, W., Franklin, I., Grady, D., Hamilton-Miller, J. M. T., Iliffe, A.: Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob. Agents Chemother. 26 (1984) 757–761.
Pecquet, S., Andrémont, A., Tancrède, C.: Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. Antimicrob. Agents Chemother. 29 (1986) 1047–1052.
Pecquet, S., Andrémont, A., Tancrède, C.: Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrob. Agents Chemother. 31 (1987) 124–125.
Henning, K. J., Delencastre, H., Eagan, J., Boone, N., Brown, A., Chung, M., Wollner, N., Armstrong, D.: Vancomycin-resistantEnterococcus faecium on a pediatric oncology ward: duration of stool shedding and incidence of clinical shedding. Ped. Infect. Dis. J. 15 (1996) 848–854.
Knapp, J. S., Fox, K. K., Trees, D. L., Whittington, W. L.: Fluoroquinolone resistance inNeisseria gonorrhoeae. Emerging Infect. Dis. 3 (1997) 33–39.
Karch, H., Russmann, H., Schmidt, H., Schwarzkopf, A., Heesemann, J.: Long-term shedding and clonal turnover of enterohemorrhagicEscherichia coli O157 in diarrheal diseases. J. Clin. Microbiol. 33 (1995) 1602–1605.
Caugant, D. A., Levin, B. R., Selander, R. K.: Genetic diversity and temporal variation ofEcherichia coli in a human host. Genetics 98 (1981) 467–490.
Piddock, L. J. V.: Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992–1994. Drugs 49 (1995) (Suppl 2): 29–35.
Heisig, P., Tschorny, R.: Characterization of fluoroquinolone-resistant mutants ofEscherichia coli selectedin vitro. Antimicrob. Agents Chemother. 38 (1994) 1284–1291.
Piddock, L. J. V., Hall, M. C., Walters, R. N.: Phenotypic characterization of quinolone-resistant mutants ofEnterobacteriaceae selected from wild-type,gyrA type and multiply-resistant (marA) type strains. J. Antimicrob. Chemother. 28 (1991) 185–198.
van Kraaij, M. G. J., Dekker, A. W., Peters, E., Fluit, A. Verdonck, L. F., Rozenberg-Arska, M.: Emergence and complications of ciprofloxacin-resistantEscherichia coli in hematological cancer patients. Program and Abstracts of the 9th International Symposium on Infections in the Immunocompromised Host, 1996, abstr. 034.
Kern, W. V., Conrad, S., Oethinger, M., Hay, B., Trautmann, M., Kern, P., Marre, R.: Clinical and molecular epidemiology of fluoroquinolone-resistantEscherichia coli isolated from cancer patients: an update. Program and Abstracts of the 9th International Symposium on Infections in the Immunocompromised Host, Assisi, 1996, abstr. 17.
Leigh, D. A., Walsh, B., Hancock, P., Travers, G.: Pharmacokinetics of ofloxacin and the effect on the faecal flora of healthy volunteers. J. Antimicrob. Chemother. 22 (1988) (Suppl C) 115–125.
van Saene, J. J. M., van Saene, H. K. F., Leck, C. F.: Inactivation of quinolones by faeces. J. Infect. Dis. 153 (1986) 998–1000.
Ball, P.: Is resistantE. coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as prophylaxis? (editorial) Clin. Infect. Dis. 20 (1995) 561–563.
Murphy, M., Brown, A. E., Sepkowitz, K. A., Bernard, E. M., Kiehn, T. E., Armstrong, D.: Fluoroquinolone prophylaxis for the prevention of bacterial infection in patients with cancer—is it justified? Clin. Infect. Dis. 25 (1997) 346–347.
Kern, W. V.: Epidemiology of fluoroquinolone-resistantEscherichia coli among neutropenic patients. Clin. Infect. Dis. 27 (1998) 235–237.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Oethinger, M., Jellen-Ritter, A.S., Conrad, S. et al. Colonization and infection with fluoroquinolone-resistantEscherichia coli among cancer patients: Clonal analysis. Infection 26, 379–384 (1998). https://doi.org/10.1007/BF02770840
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02770840